Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)

Inclusion Criteria:

- Male or female, between the ages of 18 and 60 years

- Subject is able to learn and self-administer subcutaneous injections (a care-giver
may be trained to inject the subject)

- Subjects must have a current diagnosis of Relapsing Remitting Multiple Sclerosis
(RRMS) (according to the 2010 McDonald MS diagnostic criteria)

- Other protocol defined inclusion criteria could apply

Exclusion Criteria:

- Any multiple sclerosis categorized as primary progressive, secondary progressive or
progressive relapsing

- Allergy to mannitol, plovamer acetate, Copaxone (glatiramer acetate), Gd contrast for
MRI

- Any requirement for continuous systemic glucocorticoid administration during the
trial period. (Note: Treatment with interferons such as Avonex®, Rebif®, or
Betaseron® will be allowed until the baseline visit, as no wash-out period is needed)

- Contraindication to Copaxone use

- Other protocol defined exclusion criteria could apply